Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences

Marco Carli*, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio, Marco Scarselli

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

98 Citations (Scopus)
3 Downloads (Pure)

Abstract

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophre-nia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome (MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2D), and high blood pressure, which are responsible for reduced life expectancy and poor adherence. Importantly, there is clear evidence that early metabolic disturbances can precede weight gain, even if the latter still remains the hallmark of AAPs use. In fact, AAPs interfere profoundly with glucose and lipid homeostasis acting mostly on hypothalamus, liver, pancreatic β-cells, adipose tissue, and skeletal muscle. Their ac-tions on hypothalamic centers via dopamine, serotonin, acetylcholine, and histamine receptors affect neuropeptides and 5 AMP-activated protein kinase (AMPK) activity, thus producing a supra-physiological sympathetic outflow augmenting levels of glucagon and hepatic glucose production. In addition, altered insulin secretion, dyslipidemia, fat deposition in the liver and adipose tissues, and insulin resistance become aggravating factors for MetS. In clinical practice, among AAPs, olan-zapine and clozapine are associated with the highest risk of MetS, whereas quetiapine, risperidone, asenapine and amisulpride cause moderate alterations. The new AAPs such as ziprasidone, lurasi-done and the partial agonist aripiprazole seem more tolerable on the metabolic profile. However, these aspects must be considered together with the differences among AAPs in terms of their efficacy, where clozapine still remains the most effective. Intriguingly, there seems to be a correlation between AAP’s higher clinical efficacy and increase risk of metabolic alterations. Finally, a multidisciplinary approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a first-line strategy to avoid the MetS. In addition, pharmacological treatments are discussed as well.

Original languageEnglish
Article number238
Number of pages26
JournalPharmaceuticals
Volume14
Issue number3
DOIs
Publication statusPublished - 8 Mar 2021

Keywords

  • Atypical antipsychotics (AAPs)
  • Clozapine
  • Dyslipidemia
  • G protein-coupled receptors (GPCRs)
  • Metabolic syndrome (MetS)
  • Olanzapine
  • Type 2 diabetes
  • Weight gain

Fingerprint

Dive into the research topics of 'Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences'. Together they form a unique fingerprint.

Cite this